Medical Management Of Chronic Rhinosinusitis

 Medical care is the mainstay of treatment for chronic rhinosinusitis.Patients who do not respond to a maximal medical therapy trial are candidates for surgery. One of the methods for managing CRS that is more frequently mentioned is the maximal medical therapy trial. Reserving surgery is a backup option.

Patients with fungal infections (fungal balls) will benefit from the highest level of medical care. The primary option for such people is surgery. Surgery is the next line of treatment for persistent or recurrent sinusitis caused by germs. Medical therapy is one option in these cases.

Situations Where Medical Therapy Is Not Useful

Sinonasal illness can occasionally be a symptom of a systemic illness. Sarcoidosis, vasculitis, cystic fibrosis, and ciliary motility disorder are a few examples. Due to a mucosal defect present in these illnesses, a large gravity-dependent drainage channel is necessary to allow secretion from the sinuses to drain. Rarely is medical therapy helpful in treating these patients.

A foreign body, fungal ball, odontogenic infection, or, very infrequently, an anatomical blockage can also directly result in CRS. Medical treatment is useless in this case since surgery is required to remove the source. Medical therapy aims to minimize inflammation, lower the amount of microorganisms present, and improve ciliary function through mucus removal.

Treatment Targeting Intrinsic Mucosal Inflammation 

The cornerstone of medical therapy for CRS is glucocorticoids; nevertheless, their usage is temporary. To lessen the inflammatory route, doxycycline, long-term macrolides, and other cutting-edge methods can be administered. Systemic steroids can be substituted with macrolide steroids for patients who cannot get steroids or who need long-term steroid therapy.

Intranasal Corticosteroids 

Systemic bioavailability of intranasal corticosteroids (futicasone and metekasone, second-generation drugs) is less than 1%, indicating an excellent safety profile. Because the medicine's bioavailability—the percentage of the drug absorbed in the system—is less than 1%, it is more effective in managing symptoms.

Research has indicated that there is no proof of nasal mucosal atrophy or growth loss in children who use the medication for an extended period of time. One of the most frequent questions is whether children are experiencing negative side effects from medical therapy. No, is the response. That is far too scarce to be included into the systemic system.

 It is crucial to educate patients on delivery methods and the importance of compliance. Patients will ultimately stop complying and start to feel better.  To assist reduce inflammation, the medication is taken consistently for at least 10 to 15 days. Both compliance and the method of medicine delivery are crucial. The cross-hand approach is commonly employed to administer the medication, in which the left and right nostrils are used while the pump is oriented laterally.

 Pushing the pump delivers the medication to the nose's lateral wall, which then fills the sinus aperture. In the same way, the left nostril of the right nose faces the pump laterally, allowing the left hand to apply medication to the left nostril's lateral wall.  There are a number of approaches, including bending forward and backward, depending on the target sinus.

A significantly lower amount of medication is delivered into the sinuses in non-operated patients (those who have not had sinus surgery). Topical therapy is particularly helpful after the surgery and can be administered for greater response in alleviating the symptoms. Patients who have undergone sinus surgery have broader sinuses, which results in improved drug delivery.

Also Read: Understanding Rhinosporidiosis and Rhinoscleroma

Systemic Corticosteroids 

Trials comparing the short-term advantages of a brief 2-4 week course of oral steroids of varying doses and duration to placebo have been conducted in CRSwNP patients with nasal polyposis. It is quite effective and has been demonstrated to diminish the size of the polyps.
• Patients with CRS and polyps require preoperative steroids.
• Patients with polyps and CRS who have normal serum IgE levels are treated with macrolides.

A 20-day doxycycline regimen has been demonstrated in RCT to lower myeloperoxidase levels. Research has been done on the possible anti-inflammatory effects of doxycycline. It has been demonstrated to lessen the release of myeloperoxidase and other inflammatory mediators. The polyp will shrink when the inflammation goes down because it is a persistently inflammatory tissue that prolapses.

In the eCRS subgroup, doxycycline can be given as an adjuvant; in non-eCRS patients, macrolides may be helpful.  Antagonists of leukotriene receptors  Leukotriene receptor antagonist montelukast has been studied in trials mainly as a steroid therapy adjunct in patients with asthma and CRSwNP.

Novel Immunoregulation

Omalizumab (anti-IgE) has significantly reduced both the symptom scores and polyp size in recent small PCRCTs; mepolizumab (anti-IL-5) has a significant effect on polyp size; Omalizumab and mepolizumab are the two antibodies used in patients with CRS, especially those who have recurrence, severe symptoms, and do not respond well to medical therapy; in the event that polyp recurrences necessitizing surgical interventions, aspirin desensitization may be necessary.

Also Read: Tumors of Nose and Sinuses Types

Treatments Aimed At Reducing Microbial Load 

Doxycycline has been evaluated with oral steroids in a placebo-controlled RCT in CRSwNP and was found to have a mild but more persistent effect when compared with methylprednisolone. • Long-term macrolides are mostly utilized for an anti-inflammatory effect.

Doxycycline decreased post nasal drip, but it had no effect on ansomia, rhinorrhea, or nasal congestion. As a result, it may be used as a supplement to treat CRSwNP, but more research is needed to confirm this.

More research is required to fully comprehend the use of doxycycline and other macrolides as therapies.

 Biofilms are extremely significant since they are collections of bacteria, viruses, or other microorganisms that multiply to create a matrix that is impervious to medications and antibiotics. Thus, even in cases where the sinuses have large apertures for ventilation, the multiplication of bacteria persists. Biofilms represent one of the most crucial objectives in the treatment of chronic respiratory syndrome. Patients who have both CRS and biofilm are linked to serious illnesses and are resistant to surgical intervention.

Sinus opening surgeries are performed. There exists a layer of biofilm within the sinus. addressing it as a query. The barrier of biofilm is known to be broken by topical antibiotics and surfactants, making systemic antibiotics comparatively useless. It got within the sinuses.

Also Read: Olfactory Disorders – Pathway, Work up And Causes

Propel your ENT Residency Preparation! Access conceptual video lectures, QBank, Mock Tests, and premium study resources on the PrepLadder App. Download it today!